Discontinued — last reported Q3 '23
Goldman Sachs Group Interest Paid decreased by 7.0% to $15.68B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 16.9%, from $18.86B to $15.68B. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 85.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.13B | $1.37B | $1.13B | $1.30B | $2.44B | $6.14B | $9.14B | $13.08B | $14.50B | $15.61B | $16.84B | $16.91B | $17.99B | $18.86B | $18.86B | $15.95B | $17.00B | $16.86B | $15.68B |
| QoQ Change | — | +21.7% | -17.8% | +15.3% | +87.8% | +151.9% | +48.8% | +43.1% | +10.8% | +7.7% | +7.9% | +0.4% | +6.4% | +4.8% | +0.0% | -15.4% | +6.6% | -0.9% | -7.0% |
| YoY Change | — | — | — | — | +116.4% | +348.1% | +711.0% | +907.1% | +494.3% | +154.1% | +84.2% | +29.2% | +24.1% | +20.8% | +12.0% | -5.6% | -5.5% | -10.6% | -16.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.